Novo Nordisk reports new data for Victoza indicating reduction of cardiovascular risk in people with type 2 diabetes:
- Co announced that findings from a post-hoc analysis of the LEADER cardiovascular outcomes trial showed that treatment with Victoza resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether or not they experienced an episode of severe hypoglycaemia during the trial
- For the overall LEADER population, regardless of treatment group, people who experienced a severe hypoglycaemic episode were at a significantly greater risk of major cardiovascular adverse events (CV death, non-fatal heart attack or non-fatal stroke), CV-death or non-CV death.
- The risk of a CV event was far greater within 60 days of a severe hypoglycaemic episode occuring.
- At the same time, people treated with Victoza experienced significantly fewer episodes of severe hypoglycaemia when compared to placebo, both in addition to standard of care.
No comments:
Post a Comment